These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 10499831)

  • 1. Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis.
    Sastry PS
    Med Hypotheses; 1999 Jul; 53(1):76-7. PubMed ID: 10499831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis.
    Chofflon M; Roth S; Juillard C; Paunier AM; Juillard P; Degroote D; Grau GE
    Eur Cytokine Netw; 1997 Sep; 8(3):253-7. PubMed ID: 9346357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
    Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
    Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of thalidomide on endotoxin-induced liver injury.
    Enomoto N; Takei Y; Hirose M; Kitamura T; Ikejima K; Sato N
    Alcohol Clin Exp Res; 2003 Aug; 27(8 Suppl):2S-6S. PubMed ID: 12960498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
    Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V
    Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia.
    Shannon E; Noveck R; Sandoval F; Kamath B; Kearney M
    Transl Res; 2007 Nov; 150(5):275-80. PubMed ID: 17964516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha-308 gene polymorphism in Croatian and Slovenian multiple sclerosis patients.
    Ristić S; Lovrecić L; Starcević-Cizmarević N; Brajenović-Milić B; Sega Jazbec S; Sepcić J; Kapović M; Peterlin B
    Eur Neurol; 2007; 57(4):203-7. PubMed ID: 17268200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of geldanamycin and thalidomide on the Th1/Th2 cytokine balance in mice subjected to operative trauma.
    Nakano T; Araki K; Nakatani H; Kobayashi M; Sugimoto T; Furuya Y; Matsuoka T; Jin T; Hanazaki K
    Surgery; 2007 Apr; 141(4):490-500. PubMed ID: 17383526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of thalidomide in experimental models of post-endoscopic retrograde cholangiopancreatography pancreatitis.
    Xiong GS; Wu SM; Wang ZH; Mo JZ; Xiao SD
    J Gastroenterol Hepatol; 2007 Mar; 22(3):371-6. PubMed ID: 17295769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.
    Ysrraelit MC; Gaitán MI; Lopez AS; Correale J
    Neurology; 2008 Dec; 71(24):1948-54. PubMed ID: 19064876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis.
    Saresella M; Rolland A; Marventano I; Cavarretta R; Caputo D; Marche P; Perron H; Clerici M
    Mult Scler; 2009 Apr; 15(4):443-7. PubMed ID: 19251836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with thalidomide and production of tumor necrosis factor alpha].
    Pizarro A; Pinilla J; García-Tobaruela A
    Med Clin (Barc); 1993 Jun; 101(4):158. PubMed ID: 8355553
    [No Abstract]   [Full Text] [Related]  

  • 14. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum.
    Ferger B; Leng A; Mura A; Hengerer B; Feldon J
    J Neurochem; 2004 May; 89(4):822-33. PubMed ID: 15140182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of thalidomide on the stimulation of NF-kappaB activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line.
    Kim YS; Kim JS; Jung HC; Song IS
    Mol Cells; 2004 Apr; 17(2):210-6. PubMed ID: 15179032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
    Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A
    Haematologica; 2004 May; 89(5):552-6. PubMed ID: 15136218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of experimental colitis by thalidomide.
    Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R
    Isr Med Assoc J; 2001 Sep; 3(9):644-8. PubMed ID: 11574978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts.
    Grzasko N; Dmoszynska A; Hus M; Soroka-Wojtaszko M
    Haematologica; 2006 Mar; 91(3):386-9. PubMed ID: 16531263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis.
    Caggiula M; Batocchi AP; Frisullo G; Angelucci F; Patanella AK; Sancricca C; Nociti V; Tonali PA; Mirabella M
    Scand J Immunol; 2005 Aug; 62(2):176-82. PubMed ID: 16101825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.